BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 210 filers reported holding BRIDGEBIO PHARMA INC in Q4 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $62,145 | +62.6% | 2,357 | +6.0% | 0.00% | – |
| Q2 2023 | $38,230 | +12.8% | 2,223 | +8.7% | 0.00% | – |
| Q1 2023 | $33,903 | +160.8% | 2,045 | +13.0% | 0.00% | – |
| Q4 2022 | $13,000 | -27.8% | 1,810 | -2.4% | 0.00% | – |
| Q3 2022 | $18,000 | 0.0% | 1,855 | -4.4% | 0.00% | – |
| Q2 2022 | $18,000 | 0.0% | 1,941 | +7.3% | 0.00% | – |
| Q1 2022 | $18,000 | -35.7% | 1,809 | +4.8% | 0.00% | – |
| Q4 2021 | $28,000 | -70.2% | 1,726 | -14.0% | 0.00% | – |
| Q3 2021 | $94,000 | -23.0% | 2,007 | 0.0% | 0.00% | – |
| Q2 2021 | $122,000 | +19.6% | 2,007 | +20.5% | 0.00% | – |
| Q1 2021 | $102,000 | -19.7% | 1,666 | -6.8% | 0.00% | – |
| Q4 2020 | $127,000 | +159.2% | 1,788 | +37.0% | 0.00% | – |
| Q3 2020 | $49,000 | +14.0% | 1,305 | 0.0% | 0.00% | – |
| Q2 2020 | $43,000 | +79.2% | 1,305 | +57.2% | 0.00% | – |
| Q1 2020 | $24,000 | – | 830 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 3,835,722 | $103,449,000 | 44.18% |
| Kohlberg Kravis Roberts & Co. L.P. | 36,900,661 | $995,211,000 | 12.26% |
| SC US (TTGP), LTD. | 2,544,738 | $68,632,000 | 4.69% |
| Cormorant Asset Management, LP | 2,780,885 | $75,000,000 | 4.31% |
| Perceptive Advisors | 6,706,268 | $180,868,000 | 4.15% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $717,968,000 | 3.22% |
| Hillhouse Capital Management | 2,035,790 | $54,905,000 | 1.75% |
| Alpine Group USVI, LLC | 20,000 | $539,000 | 1.70% |
| HHLR ADVISORS, LTD. | 2,352,900 | $63,458,000 | 1.42% |
| SCGE MANAGEMENT, L.P. | 588,235 | $15,865,000 | 0.79% |